Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Nesyrgy, are a calcium channel blocker and a beta blocker presented as oral tablets for oral use. They treat hypertension in adult patients by lowering blood pressure and reducing cardiac workload.

GNH USA supplies Nesyrgy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Nesyrgy combines amlodipine and nebivolol to manage hypertension, a primary disorder of the cardiovascular system.

- Essential hypertension: reduces both systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: lowers elevated systolic pressure in older adults. - Uncontrolled hypertension: assists in achieving blood pressure control when monotherapy is insufficient.

Nesyrgy may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring during the first weeks of therapy. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness or light‑headedness: especially when standing quickly. - Flushing: transient warmth and redness of the skin. - Fatigue: general feeling of tiredness. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: abnormally slow heart rate that may cause fainting. - Heart block: impairment of electrical conduction in the heart. - Angioedema: swelling of face, lips, tongue, or throat. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating Nesyrgy, clinicians should evaluate several safety considerations to minimize risk.

- Monitor blood pressure: check regularly to ensure therapeutic response and avoid hypotension. - Assess cardiac function: evaluate heart rate and ECG, especially in patients with conduction disorders. - Use caution in hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Avoid abrupt discontinuation: tapering helps prevent rebound hypertension. - Exercise caution in elderly patients: increased sensitivity to blood‑pressure‑lowering effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nesyrgy can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase amlodipine levels and risk of hypotension. - Combined use with other antihypertensives (e.g., ACE inhibitors, diuretics): can cause excessive blood‑pressure reduction. - Grapefruit juice: enhances calcium‑channel blocker exposure. - Concomitant non‑selective beta‑blockers: may exacerbate bradycardia.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect. - Diuretics: can increase risk of electrolyte imbalance and renal function changes. - Calcium supplements or antacids: may reduce amlodipine absorption. - CYP2D6 substrates (e.g., metoprolol): nebivolol metabolism may be altered, requiring dose review.